KRAS and colorectal carcinoma: Additionally, various new generations of microarray-based technologies, comparing same given cells with/without KRAS mutation by knocking-down and overexpressing the KRAS gene accordingly, may be another helpful way in defining new targets for KRAS-mutant CRC treatment [5], [6].